Drug intelligence / Profile preview

RZ-002

Development stage: Preclinical
Lead developer: Rznomics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

RZ-002 is a gene therapy drug candidate developed by Rznomics. It functions as a telomerase activator and utilizes gene transference technology. The primary mechanism involves activating telomerase, an enzyme associated with cellular immortality and cancer cell proliferation. The therapy is being investigated for its potential in treating neoplasms, particularly glioblastoma, as well as other nervous system diseases. As of June 2025, the highest development status for RZ-002 is preclinical[1].

Targets

Human telomerase reverse transcriptase mRNA

Beyond the preview

Go deeper on RZ-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RZ-002.

Explore the full profile